London-based MiNA Therapeutics, a HealthTech firm creating new medicine via gene activation, has completed a £23m ($30m) Series A equity financing led by aMoon, Israel’s largest HealthTech and life sciences venture fund, with participation from existing investors.
The proceeds from the financing will be used to advance MiNA’s pipeline of proprietary therapeutics, and support the continued clinical development of its lead candidate, MTL-CEBPA, as a combination treatment in cancer.
The treatment is said to reduce immune suppression in the tumour microenvironment.
As part of the Series A financing, Dr. Gur Roshwalb, M.D., M.B.A., Managing Director at aMoon, has joined the Board of Directors at MiNA Therapeutics.
“Since the inception of MiNA Therapeutics, we have been focused on advancing the Company by validating our innovative therapeutic approach in patients and establishing strategic collaborations with leading academic institutions and industry partners,” said Robert Habib, CEO of MiNA Therapeutics.
“This financing represents an important step in our evolution that will not only fund our continued clinical development in patients with cancer but will also enable us to further explore the potential of our pioneering approach in therapeutic areas beyond oncology. We are grateful for the support from our existing investors and are honoured to welcome aMoon to MiNA.”
Dr. Gur Roshwalb, Managing Director at aMoon added: “To date, MiNA’s innovative small activating RNA therapeutic approach has demonstrated the potential to modulate previously undruggable targets in difficult-to-treat indications such as liver cancer,” said
“We strongly believe in the potential of this new class of medicines and look forward to collaborating with the team at MiNA to support the continued growth of this technology platform.”
The firm said its saRNA medicines have the potential to transform the therapeutic landscape of cancer and other severe metabolic and genetic diseases.